The distinctive nature of HER2-positive gastric cancers

Eur J Surg Oncol. 2015 Mar;41(3):271-3. doi: 10.1016/j.ejso.2014.12.007. Epub 2015 Jan 10.

Authors

L Marano¹, F Roviello²

Affiliations

¹ Unit of General and Minimally Invasive Surgery, Department of Medicine, Surgery and Neurosciences, University of Siena, Viale Mario Bracci, 16, 53100 Siena, Italy. Electronic address: marano.luigi@email.it.
² Unit of General and Minimally Invasive Surgery, Department of Medicine, Surgery and Neurosciences, University of Siena, Viale Mario Bracci, 16, 53100 Siena, Italy.

PMID: 25605551
DOI: 10.1016/j.ejso.2014.12.007

No abstract available

Keywords: Gastric cancer; HER2; Targeted therapy; Trastuzumab.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use
Carcinoma / drug therapy
Carcinoma / genetics*
Gene Amplification
Genes, erbB-2 / genetics*
Humans
Stomach Neoplasms / drug therapy
Stomach Neoplasms / genetics*
Trastuzumab

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Trastuzumab